Ventyx Biosciences (NASDAQ:VTYX) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Key Points

• Ventyx Biosciences reported a quarterly loss of ($0.38) EPS, exceeding the consensus estimate of ($0.45) by $0.07.
• The company's stock rose by 19.1% to $2.81 after the earnings announcement, with a trading volume significantly higher than its average.
• Institutional ownership stands at 97.88%, with major increases in stakes from firms like AQR Capital Management and Acadian Asset Management.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.07, Zacks reports.

Ventyx Biosciences Stock Up 19.1%

VTYX traded up $0.45 on Friday, hitting $2.81. The company's stock had a trading volume of 1,892,363 shares, compared to its average volume of 952,532. The company's 50 day simple moving average is $2.55 and its 200-day simple moving average is $1.82. The firm has a market cap of $199.96 million, a P/E ratio of -1.67 and a beta of 0.97. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $3.39.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC lifted its stake in Ventyx Biosciences by 925.6% in the 1st quarter. AQR Capital Management LLC now owns 880,222 shares of the company's stock worth $1,012,000 after purchasing an additional 794,401 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Ventyx Biosciences by 443.8% in the 1st quarter. Acadian Asset Management LLC now owns 537,054 shares of the company's stock worth $614,000 after purchasing an additional 438,286 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Ventyx Biosciences in the 1st quarter worth approximately $56,000. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.